Clinical trials: Cancer Survivorship
Non-small Cell Lung Cancer, Lung Cancer
Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment
This study will use real-world data to assess prevalence of brain metastases in metastatic non-small cell lung cancer (mNSCLC) patients and its impact on associated clinical outcomes.
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, Metastatic Cancer, Brain and Central Nervous System Cancer
- Trial name
- NCT06557967
- Testing
- No drug
- Where
- United States
- Volunteers
- 22,517 people
- Sponsor
- Daiichi Sankyo
Cancer-related Fatigue, Survival
PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer
The primary objective of this study is to evaluate the efficacy of PG2 concurrent with concurrent chemoradiation therapy (CCRT) for relieving fatigue among locally advanced esophageal cancer patients who are under preoperative…
- Conditions
- Cancer-related Fatigue, Survival, Tumor, Esophageal
- Trial name
- NCT03611712
- Testing
- Astragalus Polysaccharides 500 mg
- Where
- 4 sites in Taiwan
- Volunteers
- 48 people
- Sponsor
- PhytoHealth Corporation
Ovarian Cancer, Breast Cancer
Comprehensive Outcomes for After Cancer Health
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
- Trial name
- COACH (NCT05349227)
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 7 sites in United States
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Pack Health
Glioblastoma, Glioblastoma Multiforme
MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)
MBM-02 (Tempol) is an HIF-1 and HIF-2 inhibitor that is being tested as an addition to standard of care treatment that includes radiotherapy and TMZ.
- Trial name
- NCT04874506
- Testing
- MBM-02
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Matrix Biomed, Inc.
Breast Cancer
An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)
This is an observational follow-up study on the efficacy of 1st-line treatment with Herceptin (trastuzumab) in patients with metastatic breast cancer 7 years after initiation of treatment.
- Trial name
- NCT01332981
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Hoffmann-La Roche
Ewing's Sarcoma
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
A two-part trial in patients with metastic Ewing's sarcoma. Participants in Part 1 will be randomized to receive either Vigil immunotherapy or gemcitabine and docetaxel with the objective of comparing the overall survival between…
- Trial name
- NCT02511132
- Testing
- Vigil, Temozolomide, Irinotecan
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gradalis, Inc.
Breast Cancer
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy…
- Trial name
- NCT06086340
- Testing
- Palbociclib, Aromatase Inhibitor
- Where
- United States
- Volunteers
- 779 people
- Sponsor
- Pfizer
Hormone Refractory Prostate Cancer
Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer
The purpose of this study is to compare the treatment effect of denosumab with placebo on prolonging bone metastasis-free survival in men with hormone refractory (androgen independent) prostate cancer who have no bone metastasis…
- Trial name
- NCT00286091
- Testing
- Denosumab
- Volunteers
- 1,435 people
- Sponsor
- Amgen
Breast Cancer
Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
The purpose of this study is to examine the efficacy and safety as well as the characteristics of the female hormone and study medications after administration in pre-menopausal women with estrogen receptor positive advanced…
- Trial name
- NCT01073865
- Testing
- ZD9393 (Zoladex) 10.8 mg, ZD9393 (Zoladex) 3.6 mg
- Where
- 55 sites in India, Japan and 4 more
- Volunteers
- 222 people
- Sponsor
- AstraZeneca
Liver Cancer
Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective for liver cancer.
- Trial name
- NCT00012324
- Testing
- doxorubicin hydrochloride, nolatrexed dihydrochloride
- Where
- 42 sites in United States, Canada and 1 more
- Sponsor
- Eximias Pharmaceutical
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
CemiplimAb Survivorship Epidemiology
The objectives of the study are: To describe the effectiveness of cemiplimab 350 mg administered every 3 weeks (Q3W) for treatment of patients with advanced (defined as locally advanced or metastatic [nodal or distant]) cutaneous…
- Trial name
- CASE (NCT03836105)
- Testing
- cemiplimab
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 287 people
- Sponsor
- Regeneron Pharmaceuticals
Clear Cell Renal Carcinoma
TroVax Renal Immunotherapy Survival Trial
The purpose of this study is to investigate whether TroVax, when added to first line standard of care therapy, improves survival for patients with locally advanced or metastatic clear cell renal adenocarcinoma.
- Trial name
- NCT00397345
- Testing
- Trovax, Standard of care therapy
- Where
- 152 sites in United States, France and 8 more
- Volunteers
- 733 people
- Sponsor
- Oxford BioMedica
Carcinoma, Non-Small-Cell Lung
Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)
Primary objective of the study's Safety run-in: To determine the maximum tolerated dose (MTD) of cilengitide in combination with cetuximab, and platinum-based chemotherapy (cisplatin/vinorelbine or cisplatin/gemcitabine).
- Trial name
- CERTO (NCT00842712)
- Testing
- Cilengitide, Cetuximab, Cisplatin
- Where
- 44 sites in Belgium, Czechia and 6 more
- Volunteers
- 232 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metastatic Melanoma, Unresectable Melanoma
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Phase 3, multicenter, international, open-label, randomized, 2-arm trial investigating the safety and efficacy of IO102-IO103 in combination with pembrolizumab as first-line treatment for patients with previously untreated…
- Trial name
- NCT05155254
- Testing
- IO102-IO103, Pembrolizumab
- Where
- 112 sites in United States, Australia and 14 more
- Volunteers
- 407 people
- Sponsor
- IO Biotech
Renal Cell Carcinoma
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
- Trial name
- NCT03592472
- Testing
- Pazopanib, Abexinostat
- Where
- 38 sites in United States, China and 4 more
- Volunteers
- 413 people
- Sponsor
- Xynomic Pharmaceuticals, Inc.
Breast Neoplasms, Neoplasms, Hormone-Dependent
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the…
- Trial name
- NCT00267553
- Testing
- Atamestane, toremifene, letrozole
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- Intarcia Therapeutics
Carcinoma, Hepatocellular, Liver Neoplasms
A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
The purpose of the study is to assess the survival of patients treated with Litx™ versus standard of care therapies in the treatment of unresectable hepatocellular carcinoma (HCC), and to demonstrate the safety of Litx™ therapy.
- Trial name
- NCT00355355
- Testing
- Talaporfin sodium, Interstitial Light Emitting Diodes, Percutaneous placement of device in the liver
- Where
- 34 sites in Croatia, Hong Kong and 9 more
- Volunteers
- 208 people
- Sponsor
- Light Sciences Oncology
Acute Myeloid Leukemia (AML)
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
The purpose of this study was to confirm the preliminary evidence from early clinical trials that midostaurin may provide clinical benefit not only to AML patients with the FLT3-mutations but also in FLT3-MN (SR<0.05) AML (FLT3…
- Trial name
- NCT03512197
- Testing
- Midostaurin, Chemotherapy
- Where
- 133 sites in United States, Argentina and 18 more
- Volunteers
- 511 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Neoplasm Metastasis
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
The purpose of this study is to assess the impact on tumor progression as evaluated by progression-free survival (PFS) of epoetin alfa plus standard supportive care as compared with standard supportive care alone (packed red…
- Trial name
- NCT00338286
- Testing
- Standard supportive care (packed RBC transfusion), epoetin alfa + packed RBC transfusion
- Where
- 174 sites in United States, Argentina and 19 more
- Volunteers
- 2,098 people
- Sponsor
- Janssen Research & Development, LLC
Breast Cancer
A Study of Xeloda (Capecitabine) in Breast Cancer Patients With Central Nervous System (CNS) Progression
This single arm study will assess the efficacy of Xeloda in the treatment of brain metastases in breast cancer patients with central nervous system (CNS) progression after whole brain radiotherapy.
- Trial name
- NCT01077726
- Testing
- capecitabine [Xeloda]
- Where
- 12 sites in France
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche